← All trials
NCT05704894
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 31, 2023
- Primary completion
- May 31, 2025
- Completion date
- Nov 30, 2025
- First posted
- Jan 30, 2023
- Last posted
- Jan 30, 2023
- Enrollment
- 320
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Blau Farmacêutica S.A.Lead sponsor
- Blau Farmacêutica S.A.Study director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.